{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T12:11:41Z","timestamp":1769515901948,"version":"3.49.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T00:00:00Z","timestamp":1597449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology, Transfusion and Cell Therapy"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.htct.2020.06.015","type":"journal-article","created":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T17:04:35Z","timestamp":1598029475000},"page":"303-308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A real life use of ruxolitinib in patients with acute and chronic graft versus host disease refractory to corticosteroid treatment in Latin American patients"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3715-9886","authenticated-orcid":false,"given":"Mauricio","family":"Sarmiento","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Jara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Soto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Uribe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauricio","family":"Ocqueteau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Bertin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.htct.2020.06.015_bib0100","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S1470-2045(00)00153-4","article-title":"Haemopoietic stem-cell transplantation: recent progress and future promise","volume":"1","author":"Craddock","year":"2000","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.htct.2020.06.015_bib0105","doi-asserted-by":"crossref","first-page":"601953","DOI":"10.1155\/2011\/601953","article-title":"Steroid-refractory acute GVHD: predictors and outcomes","volume":"2011","author":"Westin","year":"2011","journal-title":"Adv Hematol"},{"issue":"5","key":"10.1016\/j.htct.2020.06.015_bib0110","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s12185-015-1785-1","article-title":"State-of-the-art acute and chronic GVHD treatment","volume":"101","author":"Jamil","year":"2015","journal-title":"Int J Hematol"},{"issue":"1","key":"10.1016\/j.htct.2020.06.015_bib0115","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1182\/asheducation-2017.1.639","article-title":"Extracorporeal photopheresis: cellular therapy for the treatment of acute and chronic graft-versus-host disease","volume":"2017","author":"Schneiderman","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.htct.2020.06.015_bib0120","doi-asserted-by":"crossref","first-page":"82","DOI":"10.12688\/f1000research.13167.1","article-title":"JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders","volume":"7","author":"Vainchenker","year":"2018","journal-title":"F1000Res"},{"issue":"15","key":"10.1016\/j.htct.2020.06.015_bib0125","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1182\/bloodadvances.2018013060","article-title":"How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD","volume":"2","author":"Jaglowski","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.htct.2020.06.015_bib0130","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","article-title":"Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.htct.2020.06.015_bib0135","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2012-05-399048","article-title":"Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors","volume":"120","author":"Gupta","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.htct.2020.06.015_bib0140","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/bmt.2013.173","article-title":"Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib","volume":"49","author":"Jaekel","year":"2014","journal-title":"Bone Marrow Transplantation"},{"issue":"9","key":"10.1016\/j.htct.2020.06.015_bib0145","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.4067\/S0034-98872016000900003","article-title":"Ajuste de intensidad para el trasplante hematopoy\u00e9tico alog\u00e9nico en leucemia aguda","volume":"144","author":"Sarmiento","year":"2016","journal-title":"Rev Med Chil"},{"issue":"8","key":"10.1016\/j.htct.2020.06.015_bib0150","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.exphem.2016.05.011","article-title":"History of graft-versus-host disease","volume":"44","author":"Vriesendorp","year":"2016","journal-title":"Exp Hematol"},{"issue":"22","key":"10.1016\/j.htct.2020.06.015_bib0155","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease \u2013 biologic process, prevention, and therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.htct.2020.06.015_bib0160","doi-asserted-by":"crossref","first-page":"e109799","DOI":"10.1371\/journal.pone.0109799","article-title":"Pharmacologic blockade of JAK1\/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect","volume":"9","author":"Choi","year":"2014","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.htct.2020.06.015_bib0165","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1073\/pnas.1712452115","article-title":"Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation","volume":"115","author":"Betts","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.htct.2020.06.015_bib0170","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/leu.2015.212","article-title":"Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey","volume":"29","author":"Zeiser","year":"2015","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.htct.2020.06.015_bib0175","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.bbmt.2018.09.003","article-title":"Ruxolitinib as salvage therapy for chronic graft-versus-host disease","volume":"25","author":"Modi","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.htct.2020.06.015_bib0180","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40164-017-0092-3","article-title":"Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis","volume":"6","author":"Sarmiento Maldonado","year":"2017","journal-title":"Exp Hematol Oncol"},{"issue":"5","key":"10.1016\/j.htct.2020.06.015_bib0185","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2217\/imt-2017-0156","article-title":"Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials","volume":"10","author":"Jagasia","year":"2018","journal-title":"Immunotherapy"},{"issue":"4","key":"10.1016\/j.htct.2020.06.015_bib0190","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41409-017-0068-2","article-title":"Ruxolitinib in steroid-refractory chronic graft-versus-host disease: experience of a single center","volume":"53","author":"Ferreira","year":"2018","journal-title":"Bone Marrow Transplant"}],"container-title":["Hematology, Transfusion and Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137920301176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137920301176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:33:01Z","timestamp":1762867981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2531137920301176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S2531137920301176"],"URL":"https:\/\/doi.org\/10.1016\/j.htct.2020.06.015","relation":{},"ISSN":["2531-1379"],"issn-type":[{"value":"2531-1379","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A real life use of ruxolitinib in patients with acute and chronic graft versus host disease refractory to corticosteroid treatment in Latin American patients","name":"articletitle","label":"Article Title"},{"value":"Hematology, Transfusion and Cell Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.htct.2020.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda.","name":"copyright","label":"Copyright"}]}}